Pfizer Venture Investments led the small-molecule cancer drug developer's $38.6m series C round, which included Novartis, GlaxoSmithkline, AbbVie and Astellas.

US-based oncology treatment developer Effector Therapeutics raised $38.6m yesterday in a series C round led by Pfizer Venture Investments, the strategic investment arm of pharmaceutical firm Pfizer.

Novartis Venture Fund, SR One, AbbVie Biotech Ventures and Astellas Ventures, subsidiaries of pharmaceutical companies Novartis, GlaxoSmithkline, AbbVie and Astellas respectively, also took part.

The round was filled out by Alexandria Venture Investments, the venture capital vehicle for property developer Alexandria Real Estate Equities, as well as US Venture Partners (USVP), Abingworth, Column…